Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1991-6-25
|
| pubmed:abstractText |
Pharmacokinetic studies constitute part of phase I clinical trials. Initiation of dosage regimen in phase II and III clinical trials depends on drug pharmacokinetics and the choice of dosing interval relies on the elimination rate constant. Consequently, inaccurate determination of these parameters can lead to unexpected drug levels and side-effects in patients and can delay the clinical development of the drug.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0767-3981
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
135s-140s
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading | |
| pubmed:year |
1990
|
| pubmed:articleTitle |
Do we need highly sensitive analytical techniques in phase I?
|
| pubmed:affiliation |
Pharmacie Clinique, CHU Bic?tre, Le Kremlin Bicêtre, France.
|
| pubmed:publicationType |
Journal Article,
Review
|